Updated hourlyHourly refreshMon, Oct 26, 2026
Healthcare · Education
International Journal of Antimicrobial Agents publishes data showing that BV100 reaches concentrations in lung fluid and alveolar macrophages approximately 35-fold and over 300-fold higher, respectively, than in plasma, providing a strong pharmacological rationale for BV100 use in severe CRAB pneumonia
Journal of Antimicrobial Chemotherapy publishes data showing BV100 is a mild CYP3A inducer and a mild substrate for CYP3A inhibitors, a milder drug interaction profile than rifampicin, supporting its use alongside the many medicines given to critically ill patients
Both Phase 1 datasets form part of the clinical solid pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC); trial enrollment is ongoing, with topline data read-out anticipated for early 2028
BASEL, SWITZERLAND - October 20, 2026 - BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the publication of two Phase 1 clinical pharmacology studies of BV100, its lead clinical asset, in two leading peer-reviewed journals in the field of antimicrobial therapy: the International Journal of Antimicrobial Agents, the official journal of the International Society of Antimicrobial Chemotherapy, and the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.
Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, commented: "These two papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. BV100 has very good distribution in lung fluid and alveolar macrophages, and its drug-interaction profile is mild and manageable. We are pleased to share these data with the infectious disease and critical care community as we continue to enroll patients in our Phase 3 study RIV-TARGET."
Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys, added: "Carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease, and patients fighting these life-threatening infections have very few options. These data continue to strengthen the growing scientific basis for BV100 therapy in CRABC pneumonia and bring us a step closer to delivering a much-needed new treatment option to patients and the physicians who care for them."
International Journal of Antimicrobial Agents: lung penetration study
The paper, entitled "Pulmonary Penetration of Intravenous Rifabutin in Healthy Participants: A Multiple-Dose Pharmacokinetic Study," was published in the International Journal of Antimicrobial Agents (DOI: 10.1016/j.ijantimicag.2026.108014). In 36 healthy male participants receiving BV100 (intravenous rifabutin) 300 mg every 12 hours for four days, concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively, and repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia.
Journal of Antimicrobial Chemotherapy: drug-drug interaction studies
The paper, entitled "BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole," was published in the Journal of Antimicrobial Chemotherapy (DOI: 10.1093/jac/dkag317). Across two Phase 1 studies, BV100 was shown to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. This is a milder interaction profile than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies.
BV100 is currently studied in two clinical trials: the pivotal Phase 3 global registrational trial, RIV-TARGET and the open-label Phase 2b differentiation trial, RIV-CARE in collaboration with ADVANCE-ID. In September 2026, BV100 was granted Fast Track Designation by the US FDA, under the Qualified Infectious Disease Product (QIDP) Designation received in 2019.
About BioVersys
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.
About BV100
BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative bacterial species, Acinetobacter baumannii. For the first time, BV100 allows for the targeting of the RNA-polymerase enzyme in Gram-negative bacteria with a human-suitable dose. BV100 is being developed for the treatment of infections caused by Acinetobacter baumannii calcoaceticus complex (ABC), including carbapenem-resistant ABC (CRABC) in critically important indications of ventilator associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI). BV100 was granted US FDA Fast Track Designation in 2026 and QIDP Designation in May 2019, making BV100 eligible for priority FDA review and a five-year extension of market exclusivity upon approval of the first QIDP indication.
About Acinetobacter baumannii
Acinetobacter baumannii calcoaceticus complex (ABC) are Gram-negative bacteria found in the environment (e.g., in soil and water) and an opportunistic pathogen in humans, typically infecting critically ill and immunocompromised patients, that can result in severe pneumonia and bloodstream infections in addition to affecting other parts of the body. ABC is considered a significant worldwide threat in the healthcare setting given its ability to survive for prolonged periods on surfaces, combined with its ability to develop or acquire resistance to standard of care antibiotics, e.g. carbapenems. Carbapenem-resistance as well as multi-drug resistance (MDR) rates for ABC are among the highest recorded for any bacteria in current times (The Lancet 2022; 399: 629–55). Incidence and resistance rates for ABC are trending upwards and COVID-19 has exacerbated this significantly. BioVersys forecasts the annual number of carbapenem-resistant A. baumannii infections in hospitals to have surpassed one million globally and due to the limited treatment options, such infections come with high (up to 50%) mortality rates.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
BioVersys contact
Anca Cighi, Head of IR and Communications, Tel. +41 79 949 33 09; Mail: anca.cighi@bioversys.com
For IR: IR@bioversys.com; Website: www.bioversys.com
Oct 20 · 21:15·NewMediaWire
Healthcare · Biotech & pharma
Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1 Administration at the veterinary clinic helps dog owners av
Oct 20 · 20:42·Business Wire
Healthcare · Biotech & pharma
Expands Alcon's retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access Broadens Alcon's off
Oct 20 · 20:35·Business Wire
Finance · Biotech & pharma
WESTMINSTER, Colo., October 20, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced tha
Oct 20 · 20:32·Business Wire
Finance · Biotech & pharma
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third qua
Oct 20 · 20:30·Business Wire
Finance · Healthcare
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 20, 2026 -- What is the Investigation About? On June 30, 2026, before the market opened, Unicycive disclosed that the FDA had issued a second Complete Response Letter...
Oct 20 · 20:17·PR Newswire
Healthcare · Biotech & pharma
DOWNERS GROVE, Ill., Oct. 20, 2026 -- Systech, part of Markem-Imaje and Dover and a leading provider of pharmaceutical serialization and traceability solutions, today announced the launch of two new integrated packaging solutions designed to help pharmaceutical manufacturers...
Oct 20 · 20:15·PR Newswire
Finance · Healthcare
THOUSAND OAKS, Calif., Oct. 20, 2026 -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice...
Oct 20 · 20:15·PR Newswire
Education · Sports
Deputy Speaker Thomas Tayebwa has said the Bachelor of Pharmacy programme at Mbarara University of Science and Technology (MUST) remains accredited by the National Council for Higher Education (NCHE) for the next four years despite a dispute over its professional recognition by the Pharmaceutical Society of Uganda (PSU).
Tayebwa made the remarks during the plenary sitting on Tuesday, 20 October 2026 following concerns over the PSU’s reported withdrawal of the professional recognition of the programme.
Tayebwa revealed that he contacted the NCHE Executive Director, who confirmed that the programme remains accredited.
“The students are learning and being taught an accredited course,” Tayebwa told Parliament.
He added that NCHE accredited the programme in consultation with relevant stakeholders including the Pharmaceutical Society.
The Deputy Speaker said there is an overlap in the mandates of the Pharmaceutical Society and the National Council for Higher Education under the laws governing pharmacy training. He directed the Minister for Education and Sports to present a comprehensive statement to Parliament on Thursday, 22 October 2026.
He also asked the minister to consult the Attorney General and directed the Attorney General to present the legal framework governing the matter.
The Leader of the Opposition, Hon. Joel Ssenyonyi said the concerns raised by PSU appear to extend beyond programme recognition to the qualifications of the person heading Mbarara University Department of Pharmacy.
Ssenyonyi said a letter from the professional body questioned whether the department was headed by someone with the qualifications required for the position. He urged the government and relevant authorities to address the concerns promptly to prevent further uncertainty among students and graduates.
“If it is a question of somebody heading a department who requires a particular set of qualifications, I think that should be sorted out so that students are not in disarray,” Ssenyonyi said.
Distributed by APO Group on behalf of Parliament of the Republic of Uganda.
Oct 20 · 18:47·APO Group
Healthcare · Biotech & pharma
Poster 0122 on Sunday, November 8: CD206-targeted dexamethasone prodrug was superior to systemic dexamethasone in a 309-patient randomized trial (HR 2.31; p<0.0001), with no systemic steroid added in the '005 arm; abstract positions ' 005 as a potential steroid-sparing adjunct to biologic therapy, including in PMR, sJIA,
Oct 20 · 18:46·Business Wire
Finance · AI
LOS ANGELES, CA - October 20, 2026 - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo.
The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive.
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Forward Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
Oct 20 · 18:30·NewMediaWire
Biotech & pharma
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care
Oct 20 · 17:42·GSK